07:00 , Oct 11, 2010 |  BC Week In Review  |  Company News

Brain Factory, Eisai deal

Eisai granted Brain Factory exclusive rights to develop and commercialize E1224 in Japan to treat fungal infections, excluding Chagas disease. Brain Factory plans to start Phase I testing of the prodrug of ravuconazole to treat...